Paper36733714
E3 ligase ligand optimization of Clinical PROTACs.
Jiang H and 3 others. Front Chem, 2023. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. E3 ligase ligand optimization of Clinical PROTACs. Papers, record 36733714. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36733714
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References98
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31727826 | Cellular quality control by the ubiquitin-proteasome system and autophagy. | Science | 2019 | https://conductscience.org/library/papers/31727826 | PubMed |
| 2 | 30510198 | A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. | Nat Commun | 2018 | https://conductscience.org/library/papers/30510198 | PubMed |
| 3 | 18794799 | Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. | Oncogene | 2008 | https://conductscience.org/library/papers/18794799 | PubMed |
| 4 | 25856009 | Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. | J Med Chem | 2016 | https://conductscience.org/library/papers/25856009 | PubMed |
| 5 | 32888499 | Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. | Cell Chem Biol | 2020 | https://conductscience.org/library/papers/32888499 | PubMed |
| 6 | 30397315 | A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. | Nat Cell Biol | 2018 | https://conductscience.org/library/papers/30397315 | PubMed |
| 7 | 32755583 | Macrophage K63-Linked Ubiquitination of YAP Promotes Its Nuclear Localization and Exacerbates Atherosclerosis. | Cell Rep | 2020 | https://conductscience.org/library/papers/32755583 | PubMed |
| 8 | 31580635 | Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins. | ACS Chem Biol | 2019 | https://conductscience.org/library/papers/31580635 | PubMed |
| 9 | 24355989 | Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. | Nat Rev Mol Cell Biol | 2014 | https://conductscience.org/library/papers/24355989 | PubMed |
| 10 | 34473519 | Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. | J Med Chem | 2021 | https://conductscience.org/library/papers/34473519 | PubMed |
| 11 | 12001989 | Death and anti-death: tumour resistance to apoptosis. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/12001989 | PubMed |
| 12 | 35042991 | PROTAC targeted protein degraders: the past is prologue. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/35042991 | PubMed |
| 13 | 32332723 | Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. | Nat Commun | 2020 | https://conductscience.org/library/papers/32332723 | PubMed |
| 14 | 18752944 | Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. | Bioorg Med Chem Lett | 2008 | https://conductscience.org/library/papers/18752944 | PubMed |
| 15 | 34141084 | SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression. | ACS Med Chem Lett | 2021 | https://conductscience.org/library/papers/34141084 | PubMed |
| 16 | 6305978 | Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. | J Biol Chem | 1983 | https://conductscience.org/library/papers/6305978 | PubMed |
| 17 | 7144906 | Oncogenes in solid human tumours. | Nature | 1982 | https://conductscience.org/library/papers/7144906 | PubMed |
| 18 | 31059647 | Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications. | ACS Chem Biol | 2019 | https://conductscience.org/library/papers/31059647 | PubMed |
| 19 | 31804827 | Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. | J Med Chem | 2019 | https://conductscience.org/library/papers/31804827 | PubMed |
| 20 | 22524316 | The ubiquitin code. | Annu Rev Biochem | 2012 | https://conductscience.org/library/papers/22524316 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977983 | Ubiquitination in cancer: mechanisms, signaling networks and potential therapeutic opportunities. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42977983 | PubMed |
| 42853260 | PROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification. | Cancer Chemother Pharmacol | 2026 | https://conductscience.org/library/papers/42853260 | PubMed |
| 42446682 | Coumarin derivatives as HIV-1 inhibitors: mechanistic insights and structure-activity relationships. | Med Chem Res | 2026 | https://conductscience.org/library/papers/42446682 | PubMed |
| 42097191 | Interplay between NRF2 post-translational modifications and protein-protein interactions: Perspectives from emerging structural and functional evidence. | Arch Biochem Biophys | 2026 | https://conductscience.org/library/papers/42097191 | PubMed |
| 41935385 | Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review. | Curr Top Med Chem | 2026 | https://conductscience.org/library/papers/41935385 | PubMed |
| 41821623 | Protacs in oral cancer: degrading oncogenic drivers for next-generation therapy. | Front Oral Health | 2026 | https://conductscience.org/library/papers/41821623 | PubMed |
| 41750393 | Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750393 | PubMed |
| 41611823 | Indirect ubiquitination independent of endogenous ubiquitination machinery for targeted protein degradation. | Commun Chem | 2026 | https://conductscience.org/library/papers/41611823 | PubMed |
| 41221048 | Molecular docking and dynamics in protein serine/threonine kinase drug discovery: advances, challenges, and future perspectives. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41221048 | PubMed |
| 41208892 | Role of Ubiquitin-regulated EMT in Cancer Metastasis and Chemoresistance. | Int J Biol Sci | 2025 | https://conductscience.org/library/papers/41208892 | PubMed |
| 40885723 | Targeting pregnane X receptor with a potent agonist-based PROTAC to delay colon cancer relapse. | Oncogenesis | 2025 | https://conductscience.org/library/papers/40885723 | PubMed |
| 40871058 | Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40871058 | PubMed |
| 40832528 | Discovery of Small-Molecule Ligands for the E3 Ligase STUB1/CHIP from a DNA-Encoded Library Screen. | ACS Med Chem Lett | 2025 | https://conductscience.org/library/papers/40832528 | PubMed |
| 40665123 | Mechanistic insights into PROTAC-mediated degradation through an integrated framework of molecular dynamics, free energy landscapes, and quantum mechanics: A case study on kinase degraders. | J Comput Aided Mol Des | 2025 | https://conductscience.org/library/papers/40665123 | PubMed |
| 40624317 | The changing landscape of medicinal chemistry optimization. | Nat Rev Drug Discov | 2025 | https://conductscience.org/library/papers/40624317 | PubMed |
| 40236540 | Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel-Lindau Tumor Suppressor Protein (VHL). | ACS Med Chem Lett | 2025 | https://conductscience.org/library/papers/40236540 | PubMed |
| 40113751 | The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40113751 | PubMed |
| 40012379 | Targeted Management: Unlocking the Crucial Role of PROTACs in Cancer Treatment. | Curr Drug Discov Technol | 2025 | https://conductscience.org/library/papers/40012379 | PubMed |
| 39649701 | Precision-engineered PROTACs minimize off-tissue effects in cancer therapy. | Front Mol Biosci | 2024 | https://conductscience.org/library/papers/39649701 | PubMed |
| 39614036 | Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions. | Drug Deliv Transl Res | 2025 | https://conductscience.org/library/papers/39614036 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36733714
GET https://conductscience.org/api/papers/v1/36733714/references?page=2